Clinical Trials Logo

Gastroenteritis clinical trials

View clinical trials related to Gastroenteritis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06137014 Not yet recruiting - Clinical trials for Acute Gastroenteritis

Fortified Oral Rehydration Therapy for Pediatric Diarrhea

fORT
Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to compare amino acid-fortified oral rehydration therapy (ORT) to the standard of care ORT in pediatric patients with acute gastroenteritis (AGE). The main questions it aims to answer are: - can amino acid-fortified ORT reduce the duration and severity of AGE compared to standard of care ORT? - can amino acid-fortified ORT increase the secretion of antimicrobial peptides in the gastrointestinal tract compared to standard of care ORT? Participants will be assigned to the experimental treatment (amino acid-fortified ORT) or the standard of care ORT and their disease severity, duration, and stool antimicrobial peptide content.

NCT ID: NCT06038305 Not yet recruiting - Clinical trials for Acute Gastroenteritis

Prevalence of Anemia and Growth Assessment in Acute Gastroenteritis

Start date: June 2024
Phase:
Study type: Observational

1. Assessment of the growth parameters in infants admitted with acute gastroenteritis. 2. Determine the prevalence of anemia in infants admitted with acute gastroenteritis.

NCT ID: NCT05916326 Not yet recruiting - Clinical trials for Norovirus Infections

Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)

Start date: June 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination

NCT ID: NCT05876585 Not yet recruiting - Gastroenteritis Clinical Trials

A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.

NCT ID: NCT05805618 Not yet recruiting - Gastroenteritis Clinical Trials

Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety and immunogenicity of different dose levels of the Recombinant Norovirus Hexavalent Vaccine in healthy subjects aged 18-59 years given three doses of the vaccine at 28-day intervals.

NCT ID: NCT02619201 Not yet recruiting - Vomiting Clinical Trials

Antiemetic Efficacy of Ondansetron Versus Metoclopramide

Start date: November 2015
Phase: Phase 3
Study type: Interventional

Acute gastroenteritis (GEA) is a public health problem at present, the main cause of vomiting and consultation in emergencies in children under 5 years. Worldwide, there are about 2 million deaths per year due to gastroenteritis in children under 5 years. In Mexico, the mortality rate by age in 2013, recorded 28 deaths per 100,000 boys and girls, in 2013 in our country 2.5 million children between 5 and 17 years engaged in an economic activity. The occupancy rate for the child population was 8.6: 11.4 for boys and 5.8 for girls. NICE guidance gastroenteritis defined as a transient disorder caused by an enteric infection and characterized by a sudden onset of diarrhea with or without vomiting

NCT ID: NCT01671137 Not yet recruiting - Gastroenteritis Clinical Trials

Probiotic for the Prevention of Functional Disorders in Childhood

Start date: September 2012
Phase: N/A
Study type: Interventional

The present study has several aims: 1. Establish whether Lactobacillus Rhamnosus Strain GG is able to prevent the onset of IBS in a high risk group of children enrolled after an acute gastroenteritis (the study has been powered to this aim). 2. Establish whether Lactobacillus Rhamnosus Strain GG is able to stabilize the intestinal microbiota after an acute gastroenteritis. 3. Define the intestinal microbiota of children following an acute gastroenteritis and identify, if possible, a modification of the microbiota that can predict the emergence of Irritable Bowel Syndrome.